TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05676216
Drug: Diphenhydramine + Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping with Sodium bicarbonate 66.4 mEq intravenous push when vertigo patients visit Emergency Department
Study: NCT05586568
Drug: XZP-3621 tablet and itraconazole oral liquid (for Arm1)
Normalized name: itraconazole Oral Liquid Product
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1. For period 2,the subjects will take itraconazole from Day11 to Day13，they will take itraconazole in combinaiton with XZP-3621 on Day14，then take itraconazole only, from Day15 to Day27.
Study: NCT05586568
Drug: XZP-3621 tablet and Rifampicin capsules (For Arm 2)
Normalized name: rifampicin and isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets qd on Day1 . For period 2,the subjects will take Rifampicin from Day11 to Day17，they will take Rifampicin in combinaiton with XZP-3621 on day18，then take Rifampicin only, from Day19 to Day26.
Study: NCT05586568
Drug: XZP-3621 tablet and esomeprazole tablet (For Arm3)
Normalized name: naproxen and esomeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1 . For period 2,the subjects will take esomeprazole from Day11 to Day 15，they will take esomeprazole in combinaiton with XZP-3621 on Day16.
Study: NCT06485817
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3.1mg oxycodone/70 kg body weight was administered as the main drug intervention.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later.
Study: NCT02807285
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 days, every 24 weeks.
Study: NCT05215158
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: to compare perineural (peribulbar) dexmedetomidine versus intravenous (I.V.) dexmedetomidine when used as an adjuvant with local anesthesia in adult strabismus surgery.
Study: NCT06564441
Drug: Survodutide
Normalized name: Survodutide
DrugBank: Survodutide (DB18989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survodutide
Study: NCT06564441
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion
Study: NCT06564441
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam
Study: NCT04677972
Drug: Ebselen
Normalized name: Ebselen
DrugBank: Ebselen (DB12610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione peroxidase mimetic
Study: NCT02286492
Drug: TAS-102
Normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At a dose of 35 mg/m2 administered orally twice daily for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest (1 treatment cycle)
Study: NCT05549466
Drug: Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.~Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W.
Study: NCT05549466
Drug: Apatinib, Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W.
Study: NCT05549466
Drug: Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.~Camrelizumab, iv, 200mg, D1, Q3W.
Study: NCT06025474
Drug: Vortioxetine 20Mg Tab
Normalized name: VORTIOXETINE 20MG TAB
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Encapsulated vortioxetine immediate release tablets, once daily
Study: NCT06025474
Drug: Paroxetine 20 Mg Oral Tablet
Normalized name: PARoxetine 20 mg oral tablet
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated paroxetine tablets, once daily
Study: NCT06025474
Drug: Sertraline 50 MG
Normalized name: sertraline 50 MG
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated sertraline tablets, once daily
Study: NCT06025474
Drug: Citalopram 20mg
Normalized name: Escitalopram 20mg Oral tablet
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated citalopram tablets, once daily
Study: NCT06025474
Drug: Escitalopram 10mg
Normalized name: Escitalopram 10mg Oral tablet
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated escitalopram tablets, once daily
Study: NCT06025474
Drug: Duloxetine 60 MG
Normalized name: duloxetine 60 MG
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated duloxetine tablets, once daily
Study: NCT06025474
Drug: Pregabalin 75mg
Normalized name: PREGABALIN 75MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Encapsulated pregabalin tablets, once daily
Study: NCT04833387
Drug: PD-1 antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine:Dose of 1650mg/m2,14days; Radiation:50Gy/25 fractions;IBI308: 200mg on day1 of each cycle, 3 cycles; Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
Study: NCT05549466
Drug: Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.
Study: NCT05467462
Drug: I.V carbetocin administration
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: carbetocin was intravenously administered immediately after birth of the baby.
Study: NCT05467462
Drug: I.V Oxytocin administration
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group II: Oxytocin the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord.
Study: NCT05467462
Drug: I.V carbetocin and tranexamic acid administration
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group III: carbetocin and tranexamic acid 100-mg carbetocin was intravenously administered immediately after birth of the baby and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord.
Study: NCT05467462
Drug: I.V Oxytocin and tranexamic acid administration
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group IV: oxytocin and tranexamic acid the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
Study: NCT04973891
Drug: Canagliflozin combined with metformin
Normalized name: canagliflozin / metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Canagliflozin, a novel glucose-lowering medication, has been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events.~Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.
Study: NCT04973891
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.
Study: NCT06055491
Drug: Vitamin D3 or Saline injection at ipsilateral deltoid muscle
Normalized name: vitamin D3
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: study group: 1.0mL Vitamin D3 injection control group: 1.0mL saline injection
Study: NCT05199818
Drug: Palonosetron HCl Buccal Film 0.5 mg
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palonosetron HCl Buccal Film and IV palonosetron placebo, both administered on Day 1
Study: NCT05199818
Drug: IV Palonosetron 0.25 mg
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Palonosetron and Palonosetron HCl Buccal Film placebo, both administered on Day 1
Study: NCT04731779
Drug: cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
Study: NCT05967949
Drug: chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: This subset of patients received chidamide as first-line maintenance therapy.
Study: NCT06497452
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling
Study: NCT06126354
Drug: Insulin human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
Study: NCT06126354
Drug: Octreotide Acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
Study: NCT06126354
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
Study: NCT06126354
Drug: Human Growth Hormone
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
Study: NCT06126354
Drug: Dexamethasone Oral
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Synthetic pure glucocorticoid used to induce temporary insulin resistance, administered orally as seven 1-mg doses over 72 hours.
Study: NCT06126354
Drug: 20% D-glucose (aq)
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.~(Non-investigational)
Study: NCT05205330
Drug: CR6086
Normalized name: CR6086
DrugBank: CR6086 (DB16111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral CR6086, twice a day for 14 days
Study: NCT05103020
Drug: intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks
Normalized name: methotrexate
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bevacizumab : 5mg/kg IV over 30min, day 1 or Cetuximab : 500 mg/m2 IV over 2-hr, day 1 Oxaliplatin : HAI 100mg/m2 IV over 2-hr, day 1 Leucovorin : 400mg/m2 IV over 2-hr, day 1 5-Fluorouracil : 2400mg/m2 infusion for 46-h Irinotecan : 180mg/m2 IV over 1.5-hr, day 1
Study: NCT05103020
Drug: IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab : 5mg/kg IV over 30min, day 1 or Cetuximab : 500 mg/m2 IV over 2-hr, day 1 Irinotecan : 180mg/m2 IV over 1.5-hr, day 1 Leucovorin : 400mg/m2, IV over 2-hr, day 1 5-Fluorouracil : 400mg/m2 IV bolus, day 1 5-Fluorouracil : 2400mg/m2, infusion for 46-h
Study: NCT06138327
Drug: BMN 255
Normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT01053702
Drug: R475
Normalized name: Romosozumab
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT06068179
Drug: methimazole, oral, 10mg
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole 15-30mg daily initially then titrate to maintenance dose.
Study: NCT05130970
Drug: Garadacimab
Normalized name: Garadacimab
DrugBank: Garadacimab (DB15629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received garadacimab intravenous (IV) loading dose followed by 3 subcutaneous (SC) doses.
Study: NCT06024213
Drug: indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intervention description: indocyanine green (5 to 10 mg \[ie, 2 to 4 mL of a 2.5 mg/mL solution\]) administered by periareolar or peritumoural route
Study: NCT06024213
Drug: methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1%), 2-5 mL administered by periareolar or peritumoural route
Study: NCT06024213
Drug: Technetium (99mTc)
Normalized name: Technetium (99mTc) HMPAO
DrugBank: Technetium Tc-99m (DB14227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (99mTc, 0.2 - 0.4 mCi in 0.4 mL administered by periareolar or peritumoural route
Study: NCT04805710
Drug: clopidogrel combined with rivaroxaban arm
Normalized name: Rivaroxaban
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients who have been selected will be randomized to the clopidogrel combined with rivaroxaban arm. clopidogrel 75 mg once daily and rivaroxaban 10 mg once daily
Study: NCT04369560
Drug: Gadobutrol intravesical administration (4mM)
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A paramagnetic macrocyclic gadolinium-based contrast agent administered intravenously for use in magnetic resonance imaging. Contrast-enhancement is a result of the neutral complex of gadolinium and dihydroxy-hydroxymethylpropyl- tetraazacyclododecane-triacetic acid (butrol).
Study: NCT04369560
Drug: Ferumoxytol intravesical administration (5 mM)
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: An iron preparation (Fe3O4) approved for intravenous treatment of anemia in the setting of renal failure, comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution.
Study: NCT05821309
Drug: PEG 3350
Normalized name: PEG 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
Study: NCT05821309
Drug: Glycerin
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin will be given to patients based on standard of care, at the discretion of the pediatric gastroenterology and pediatric surgery teams. Glycerin administration will not be randomized. For secondary analysis, the microbiomes of those who have and have not received glycerin will be compared.
Study: NCT05358821
Drug: SAGE-718
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-718 oral softgel lipid capsules
Study: NCT05378061
Drug: Pituitary adenylate cyclase activating polypeptide-38
Normalized name: SH-polypeptide-42
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will be allocated to receive continuous intravenous infusion of 10 pmol/kg/min PACAP-38.
Study: NCT06118411
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Tablets
Study: NCT05379413
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum neurotoxin (BoNT) Type A injection with either OnaBoNT-A, AboBoNT-A, IncoBoNT-A
Study: NCT05257902
Drug: choline alphoscerate
Normalized name: Choline alphoscerate
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg bid/day
Study: NCT05095168
Drug: CAN106
Normalized name: Immunoglobulin G [27-histidine,57-histidine,253-tyrosine,255- threonine,257-glutamic acid], anti-(human complement C5) (human monoclonal CAN106 hybrid y2-chain CH1-hinge region/y4-chain CH2- CH3 region), disulfide with human monoclonal CAN106 Kappa-chain, dimer
DrugBank: CAN-106 (DB18389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAN106 is a selective inhibitor of complement activation, which binds to the complement component C5.
Study: NCT04374279
Drug: Bicalutamide 150 Mg Oral Tablet
Normalized name: bicalutamide 150 MG Oral Tablet
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 150 mg by mouth daily for 7 days
Study: NCT04576091
Drug: Elimusertib
Normalized name: Elimusertib
DrugBank: Elimusertib (DB19041)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05570409
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 1g bid for 6 months
Study: NCT03865836
Drug: AT2221
Normalized name: AT2221
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04736329
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan (20 up to 80mg) for RAAS inhibition, as part of heart failure therapy.
Study: NCT06364956
Drug: Tislelizumab combined with two predefined dose groups of palbociclib
Normalized name: Tislelizumab
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tislelizumab, 200mg q3W, combined with two predefined dose groups of palbociclib: 100mg QD and 125mg QD, separately.
Study: NCT06364956
Drug: RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After the exploration of Tislelizumab, 200mg q3W combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
Study: NCT05713578
Drug: apantamide+docetaxel+ADT
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally; ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT to be used in each research center are determined by the investigator; The treatment of docetaxel was started within 6 weeks after the treatment of apantamide and ADT. The single dose of docetaxel was 75 mg/m2, intravenous drip for 1 hour, repeated every 3 weeks, and docetaxel lasted for 6 cycles.
Study: NCT05578482
Drug: Dicloxacillin Oral Capsule
Normalized name: dicloxacillin Oral Capsule
DrugBank: Dicloxacillin (DB00485)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized to either systemic dicloxacillin \& elocon or placebo \& elocon
Study: NCT05491044
Drug: orelabrutinib
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib 150mg po qd d1-28, up to 2 years or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).
Study: NCT00002109
Drug: Thymopentin
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002109
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002109
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002109
Drug: Zalcitabine
Normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002109
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05109702
Drug: 0.25% Tanfanercept Ophthalmic Solution
DrugBank: Tanfanercept (DB19142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanfanercept ophthalmic solution.
Study: NCT05417841
Drug: Insulin Degludec and Insulin Aspart Injection
Normalized name: insulin aspart, human / insulin degludec
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: To evaluate the efficacy and safety of the IDegAsp BID in T2DM
Study: NCT05417841
Drug: Insulin Aspart Injection
Normalized name: Insulin Aspart Injection
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: To evaluate the efficacy and safety of the IDegAsp QD plus IAsp BID in T2DM
Study: NCT06524596
Drug: tartaric acid butorphanol
Normalized name: Tartaric Acid
DrugBank: Butorphanol (DB00611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The group received 0.02 mg/kg tartaric acid butorphanol intravenously over 5 minutes, 30 minutes before anaesthesia induction
Study: NCT05317013
Drug: CBD
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD